Suppr超能文献

结构性心脏病患者导管消融术后胺碘酮的停药或剂量减少。

Amiodarone Discontinuation or Dose Reduction Following Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease.

机构信息

Electrophysiology Section, Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

出版信息

JACC Clin Electrophysiol. 2017 May;3(5):503-511. doi: 10.1016/j.jacep.2016.11.005. Epub 2017 Feb 1.

Abstract

OBJECTIVES

This study sought to examine long-term outcomes in patients with structural heart disease in whom amiodarone was reduced/discontinued after ventricular tachycardia (VT) ablation.

BACKGROUND

VT in patients with structural heart disease increases morbidity and mortality. Amiodarone can decrease VT burden, but long-term use may result in organ toxicities and possibly increased mortality. Catheter ablation can also decrease VT burden. Whether amiodarone can be safely reduced/discontinued following ablation remains unknown.

METHODS

We studied consecutive patients undergoing VT ablation from 2008 to 2011, typically followed by noninvasive programmed stimulation several days later. Patients were divided into 3 groups by amiodarone use: group A-amiodarone reduced/discontinued following ablation; group B-amiodarone not reduced; group C-not on amiodarone at time of ablation. Baseline characteristics and outcomes were compared between groups.

RESULTS

Overall, 231 patients (90% male; mean age: 63.4 ± 12.9 years; 53.7% ischemic cardiomyopathy) were included (group A: 99 patients; group B: 29 patients; group C: 103 patients). Group B patients were older with more advanced heart failure. Group A patients less frequently had inducible VT at the end of ablation or noninvasive programmed stimulation. In follow-up, 1-year VT-free survival was similar between groups (p = 0.10). Mortality was highest in group B (p < 0.001). Higher amiodarone dose after ablation (hazard ratio: 1.23; 95% confidence interval: 1.03 to 1.47; p = 0.02) was independently associated with shorter time to death.

CONCLUSIONS

After successful VT ablation, as confirmed by noninducibility at the end of ablation and noninvasive programmed stimulation, amiodarone may be safely reduced/discontinued without an unacceptable increase in VT recurrence. Reduction/discontinuation of amiodarone should be considered an important goal of VT ablation.

摘要

目的

本研究旨在探讨结构性心脏病患者在室性心动过速(VT)消融后减少/停用胺碘酮的长期预后。

背景

结构性心脏病患者的 VT 会增加发病率和死亡率。胺碘酮可降低 VT 负荷,但长期使用可能导致器官毒性,并且可能增加死亡率。导管消融也可降低 VT 负荷。消融后胺碘酮是否可以安全减少/停用尚不清楚。

方法

我们研究了 2008 年至 2011 年间接受 VT 消融的连续患者,通常在随后几天进行非侵入性程控刺激。根据胺碘酮的使用情况,患者分为 3 组:A 组-消融后减少/停用胺碘酮;B 组-未减少胺碘酮;C 组-消融时未用胺碘酮。比较各组的基线特征和结局。

结果

共有 231 例患者(90%为男性;平均年龄:63.4±12.9 岁;53.7%为缺血性心肌病)入组(A 组:99 例;B 组:29 例;C 组:103 例)。B 组患者年龄较大,心力衰竭程度更重。A 组患者在消融结束或非侵入性程控刺激时诱导性 VT 较少。随访期间,各组 1 年 VT 无复发率相似(p=0.10)。B 组死亡率最高(p<0.001)。消融后胺碘酮剂量较高(风险比:1.23;95%置信区间:1.03 至 1.47;p=0.02)与死亡时间缩短独立相关。

结论

在消融后 VT 得到证实(通过消融结束时的非诱导性和非侵入性程控刺激证实),胺碘酮可安全减少/停用,而 VT 复发的风险不会增加。减少/停用胺碘酮应被视为 VT 消融的一个重要目标。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验